Vertex Pharma shares close up 8.3% in best day since Dec. 2023
TL;DR
Vertex Pharmaceuticals shares surged 8.3% on March 10, 2026, their best day since December 2023, driven by positive Phase 3 trial results for Povetacicept in IgA nephropathy and strong demand for cystic fibrosis therapies. The company's robust pipeline and recent financial performance fuel investor optimism for long-term growth.
Tags
Vertex Pharmaceuticals Inc. (VRTX) shares closed up 8.3% on March 10, 2026, marking the stock's largest single-day gain since December 2023, driven by positive developments in its clinical pipeline and ongoing demand for cystic fibrosis (CF) therapies according to market data. The surge followed the company's announcement of favorable week 36 interim results from the RAINIER Phase 3 trial of Povetacicept for IgA nephropathy, meeting all primary and secondary endpoints. This milestone has positioned the experimental therapy as a potential treatment for the chronic kidney disease, fueling investor optimism.
The stock's performance builds on recent momentum, including a 6% gain in early March, which had set it on track for its highest closing price since May 2025 as reported. Vertex also reported strong fourth-quarter and full-year 2025 financial results in February, with revenue bolstered by sustained demand for its CF medications, such as Kalydeco, Orkambi, and Trikafta according to earnings reports.
Looking ahead, Vertex is scheduled to present new data on JOURNAVX, its pain management therapy, at upcoming investor conferences, including the TD Cowen 46th Annual Health Care Conference in March as scheduled. Analysts note that the company's robust pipeline and market leadership in CF treatments continue to underpin long-term growth prospects, though near-term success will depend on regulatory and commercial progress for emerging assets like Povetacicept.
